## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.64 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (53% of avg), momentum weakening (-7.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($96.75)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. RVTY: Life sciences, software, and diagnostics show growth, with China stabilizing and margins set to improve**
- Source: TradingView | 20251202T180736 | Bullish | Relevance: 98%
- Revvity (RVTY) is experiencing increased activity in life sciences and instrumentation, with strong growth driven by software and AI initiatives. Immunodiagnostics and newborn screening are expanding, and the diagnostics sector in China is stabilizing after policy changes. The company anticipates positive margin and revenue outlooks for 2026.

**2. (RVTY) Movement as an Input in Quant Signal Sets**
- Source: Stock Traders Daily | 20251130T175600 | Neutral | Relevance: 98%
- This article analyzes Revvity Inc. (NASDAQ: RVTY) using AI-generated quant signal sets, highlighting a strong near and mid-term sentiment but a weak long-term outlook with elevated downside risk. It provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with a multi-timeframe signal analysis. The report details support and resistance levels for different time horizons and offers access to real-time signals and personalized dashboard features.

**3. Jim Cramer Recently Discussed These 9 Stocks**
- Source: Insider Monkey | 20251202T232300 | Bullish | Relevance: 96%
- Jim Cramer recently discussed nine stocks, highlighting Revvity, Inc. (NYSE:RVTY) due to its cheap valuation despite past disappointing results. Cramer noted Revvity's improved performance in October and raised full-year earnings forecast, positioning it as the most affordable in its group. The company provides essential instruments, reagents, software, and sequencing services for genetic testing and research.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Elevated short interest (9.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.64 indicates undervaluation relative to growth. Forward P/E 19.4x stretched relative to 8% growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.0B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.64 |
| Forward P/E | 19.4 |
| Current P/E | 20.9 |
| YoY Growth | 7.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 12.7% to 5.2% (-7.5% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 91st percentile. MRS_5 (-1.8%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 7.0% shows strong absolute momentum above own 20MA. Outperforming sector by 5.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.95), confirming momentum. Volume at 53% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.15% (CS: 91) | Strong |
| RSI_14 | 63.7 | Neutral |
| MACD Histogram | 0.95 | Bullish |
| vs SMA20 | 1.070x | Above |
| vs SMA50 | 1.099x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $102.73
- **Stop Loss:** $96.75 (5.8% risk)
- **Target:** $114.69 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 167
- **Position Value:** $17,155.91
- **Portfolio %:** 17.16%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*